Dr. Joshi on Durvalumab/RT Combo in Locally Advanced Urothelial Cancer

Video

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Monika Joshi, MD, associate professor, Division of Hematology/Oncology, Penn State Hershey Medical Center, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

This type of regimen has been studied in the preclinical setting, as well as the clinical setting. For example, the PACIFIC study treated patients with stage III non—small cell lung cancer with durvalumab following concurrent chemoradiation. This trial inspired the phase I/II DUART/BTCRC-GU15-023 study in patients with urothelial cancer of the bladder, Joshi explains.

Radiation primes the immune system and causes more DNA damage to cancer cells. It also causes an increase in antigen presentation, which leads to a pro-inflammatory environment. When immunotherapy and radiation therapy are combined, the hypothesis of the study was that this environment would increase response rates and patients would have improved clinical outcomes, concludes Joshi.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,